Pharmacogenetics — Tailoring Treatment for the Outliers
- 19 February 2009
- journal article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 360 (8), 811-813
- https://doi.org/10.1056/nejme0810630
Abstract
If it were not for the great variability among individuals, medicine might as well be a science and not an art.— Sir William Osler (1892)Over the past half century, biomedical science has developed randomized, controlled clinical-trial methods that can distinguish treatment effects from the noise of human variability. Positive results from tests of a treatment in a randomized, controlled trial provide great confidence that an intervention improves a prespecified outcome in a population defined by explicit entry criteria. These methods are rightly venerated because they have helped move medicine from anecdote to science and have largely brought about . . .Keywords
This publication has 4 references indexed in Scilit:
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirThe New England Journal of Medicine, 2008
- Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene LocusJNCI Journal of the National Cancer Institute, 1999